{"id":1342,"date":"2026-02-09T13:00:37","date_gmt":"2026-02-09T13:00:37","guid":{"rendered":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/02\/09\/actrims-2026-fenebrutinib-matches-ocrevus-in-ppms-trial\/"},"modified":"2026-02-09T13:00:37","modified_gmt":"2026-02-09T13:00:37","slug":"actrims-2026-fenebrutinib-matches-ocrevus-in-ppms-trial","status":"publish","type":"post","link":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/02\/09\/actrims-2026-fenebrutinib-matches-ocrevus-in-ppms-trial\/","title":{"rendered":"ACTRIMS 2026: Fenebrutinib matches Ocrevus in PPMS trial"},"content":{"rendered":"<p><a href=\"https:\/\/multiplesclerosisnewstoday.com\/actrims\/2026\/02\/09\/actrims-2026-fenebrutinib-matches-ocrevus-ppms-trial\/\" title=\"ACTRIMS 2026: Fenebrutinib matches Ocrevus in PPMS trial\" rel=\"nofollow\"><img loading=\"lazy\" decoding=\"async\" width=\"800\" height=\"534\" src=\"https:\/\/multiplesclerosisnewstoday.com\/wp-content\/uploads\/2026\/02\/iStock-2232376902-800x534.jpg\" class=\"webfeedsFeaturedVisual wp-post-image\" alt=\"A photo shows a hand holding a pill.\" style=\"margin: auto;margin-bottom: 15px;max-width: 100%\" data-wp-pid=\"159142\" \/><\/a><\/p>\n<p>The investigational BTK inhibitor fenebrutinib was as effective as the approved therapy Ocrevus (ocrelizumab) at reducing the risk of disability progression in people with primary progressive multiple sclerosis\u00a0(PPMS), meeting the main goal of a Phase 3 trial. According to fenebrutinib\u2019s developer, Genentech, the therapy is the first in more than 10 years to slow disability [&#8230;]<\/p>\n<p>The post <a href=\"https:\/\/multiplesclerosisnewstoday.com\/actrims\/2026\/02\/09\/actrims-2026-fenebrutinib-matches-ocrevus-ppms-trial\/\">ACTRIMS 2026: Fenebrutinib matches Ocrevus in PPMS trial<\/a> appeared first on <a href=\"https:\/\/multiplesclerosisnewstoday.com\">Multiple Sclerosis News Today<\/a>.<\/p>\n<p><em>Source: <a href=\"https:\/\/multiplesclerosisnewstoday.com\/actrims\/2026\/02\/09\/actrims-2026-fenebrutinib-matches-ocrevus-ppms-trial\/\" rel=\"nofollow noopener\" target=\"_blank\">multiplesclerosisnewstoday.com<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The investigational BTK inhibitor fenebrutinib was as effective as the approved therapy Ocrevus (ocrelizumab) at reducing the risk of disability progression in people with primary progressive multiple sclerosis\u00a0(PPMS), meeting the main goal of a Phase 3 trial. According to fenebrutinib\u2019s developer, Genentech, the therapy is the first in more than 10 years to slow disability&#8230;<\/p>\n","protected":false},"author":0,"featured_media":1343,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[11,15,9,8,13,14,12,10],"class_list":["post-1342","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-multiple-sclerosis-research","tag-brain-repair","tag-marburg-type-ms","tag-ms","tag-multiple-sclerosis","tag-myelin","tag-neuroregeneration","tag-oligodendrocyte","tag-remyelination"],"_links":{"self":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/1342","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=1342"}],"version-history":[{"count":0,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/1342\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media\/1343"}],"wp:attachment":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=1342"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=1342"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=1342"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}